-
公开(公告)号：WO2011025964A3
公开(公告)日：2011-04-21
申请号：PCT/US2010047006
申请日：2010-08-27
Applicant: ABBOTT LAB , BENATUIL LORENZO , BOGHAERT ERWIN R , GU JIJIE , HARRIS MARIA , HICKSON JONATHAN A , HSIEH CHUNG-MING , KUTSKOVA YULIYA , LI YINGCHUN , LIU ZHIHONG , MORGAN-LAPPE SUSAN
Inventor： BENATUIL LORENZO , BOGHAERT ERWIN R , GU JIJIE , HARRIS MARIA , HICKSON JONATHAN A , HSIEH CHUNG-MING , KUTSKOVA YULIYA , LI YINGCHUN , LIU ZHIHONG , MORGAN-LAPPE SUSAN
IPC: C07K16/28
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：WO2010102251A3
公开(公告)日：2010-11-25
申请号：PCT/US2010026424
申请日：2010-03-05
Applicant: ABBOTT LAB , HSIEH CHUNG-MING , HUGUNIN MARGARET , MURTAZA ANWAR , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , PEREZ JENNIFER M , ZHONG SUJU , TARCSA EDIT , CLABBERS ANCA , WALLACE CRAIG , BRYANT SHAUGHN H , LEDDY MARY R
Inventor： HSIEH CHUNG-MING , HUGUNIN MARGARET , MURTAZA ANWAR , MCRAE BRADFORD L , KUTSKOVA YULIYA , MEMMOTT JOHN E , PEREZ JENNIFER M , ZHONG SUJU , TARCSA EDIT , CLABBERS ANCA , WALLACE CRAIG , BRYANT SHAUGHN H , LEDDY MARY R
IPC: A61K39/395
CPC classification number: C07K16/468 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2300/00 , C07K16/241 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/50 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92
Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
Abstract translation: 描述了结合IL-17和/或IL-17F的蛋白以及其在用于治疗，预防和诊断IL-17相关疾病和检测细胞，组织，样品和组合物中的IL-17的组合物和方法中的应用。
-
3.发明申请ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF 审中-公开高级糖果终产品（RAGE）及其用途的受体抗体
公开(公告)号：WO2009136382A2
公开(公告)日：2009-11-12
申请号：PCT/IB2009051915
申请日：2009-05-08
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB , GU JIJIE , HSIEH CHUNG-MING , WU ZHEN , DIGIAMMARINO ENRICO L , LUO FENG , FOX GERARD B , HARLAN JOHN E , SCHMIDT MARTIN , LOEBBERT RALF , MUELLER REINHOLD , EBERT ULRICH , NIMMRICH VOLKER
Inventor： GU JIJIE , HSIEH CHUNG-MING , WU ZHEN , DIGIAMMARINO ENRICO L , LUO FENG , FOX GERARD B , HARLAN JOHN E , SCHMIDT MARTIN , LOEBBERT RALF , MUELLER REINHOLD , EBERT ULRICH , NIMMRICH VOLKER
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/28 , C07K16/464 , C07K2317/14 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12P21/005
Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ß and advanced glycation-end-products.
Abstract translation: 本申请涉及分离的蛋白质，特别是单克隆抗体，特别是结合RAGE蛋白质的CDR-移植的人源化抗体。 具体地说，这些抗体具有抑制RAGE与其各种配体结合的能力。 本申请中描述的抗体或其部分可用于治疗由RAGE的病理生理学配体表征或诱导的疾病或病症，例如错折叠蛋白，如淀粉样蛋白β和晚期糖基化终产物。
-
公开(公告)号：WO2011109298A3
公开(公告)日：2011-11-24
申请号：PCT/US2011026489
申请日：2011-02-28
Applicant: ABBOTT LAB , LI YINGCHUN , GU JIJIE JAMES , MORGAN-LAPPE SUSAN , CHEN MINGJIU , HSIEH CHUNG-MING
Inventor： LI YINGCHUN , GU JIJIE JAMES , MORGAN-LAPPE SUSAN , CHEN MINGJIU , HSIEH CHUNG-MING
IPC: C07K16/18
CPC classification number: C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
Abstract translation: 本文描述了DLL4结合蛋白，包括抗体，CDR-移植抗体，人源化抗体及其DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4和/或VEGF活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成。
-
公开(公告)号：WO2010039852A2
公开(公告)日：2010-04-08
申请号：PCT/US2009059059
申请日：2009-09-30
Applicant: ABBOTT LAB , HSIEH CHUNG-MING , KUTSKOVA YULIYA A , MEMMOTT JOHN E
Inventor： HSIEH CHUNG-MING , KUTSKOVA YULIYA A , MEMMOTT JOHN E
CPC classification number: C40B50/06 , C07K16/00 , C07K16/1018 , C07K16/241 , C07K16/244 , C07K2317/21 , C07K2317/622 , C12Q2563/185 , C40B40/08
Abstract: The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.
Abstract translation: 本发明的特征在于改进的体外RNA显示文库以允许来自表达文库的scFv抗体分子的可靠表达和选择。 本发明的scFv抗体文库含有改善表达scFv抗体表达的优化的缩短的域间连接体。 scFv抗体文库还包括允许识别单个文库克隆，文库或其子集的短核酸条形码。 还提供了用于产生，扩增和分光本发明的scFv抗体文库的引物。
-
Patent Agency Ranking
公开(公告)号：WO2009114093A3
公开(公告)日：2010-01-21
申请号：PCT/US2009001351
申请日：2009-03-03
Applicant: ABBOTT LAB , HSIEH CHUNG-MING , BELK JONATHAN P , PEREZ JENNIFER M , BENATUIL LORENZO
Inventor： HSIEH CHUNG-MING , BELK JONATHAN P , PEREZ JENNIFER M , BENATUIL LORENZO
Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.
Abstract translation: 本发明涉及通过电穿孔转化酵母及其突变体，其导致表达重组产物的稳定转化的酵母宿主细胞。 本发明还涉及转化的酵母细胞和文库。
-
公开(公告)号：WO2009091912A3
公开(公告)日：2009-09-24
申请号：PCT/US2009031136
申请日：2009-01-15
Applicant: ABBOTT LAB , HSIEH CHUNG-MING
Inventor： HSIEH CHUNG-MING
IPC: C12N15/00
CPC classification number: C12P21/00 , C07K16/241 , C07K2317/21 , C07K2317/52
Abstract: The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies.
Abstract translation: 本发明的特征在于哺乳动物细胞培养中用于重组蛋白表达的核酸。 本发明的附加型载体在表达SV40T Ag或爱泼斯坦 - 巴尔病毒核抗原（例如COS7或HEK293-6E细胞）的哺乳动物细胞中促进高蛋白质产生。 所述方法和系统在例如药物开发和克隆中尤为有利于制备抗体。
-
公开(公告)号：EP2340256A4
公开(公告)日：2012-03-21
申请号：EP09818451
申请日：2009-09-30
Applicant: ABBOTT LAB
Inventor： HSIEH CHUNG-MING , KUTSKOVA YULIYA A , MEMMOTT JOHN E
CPC classification number: C40B50/06 , C07K16/00 , C07K16/1018 , C07K16/241 , C07K16/244 , C07K2317/21 , C07K2317/622 , C12Q2563/185 , C40B40/08
-
公开(公告)号：EP2391652A4
公开(公告)日：2013-01-02
申请号：EP10736144
申请日：2010-01-29
Applicant: ABBOTT LAB
Inventor： HSIEH CHUNG-MING , WU CHENGBIN
IPC: C07K16/24
CPC classification number: A61K39/3955 , A61K38/00 , A61K45/06 , A61K47/6845 , C07K16/245 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL-1α binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1α and neutralize IL-1α activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, e.g., in a human subject suffering from a disorder in which IL-1α activity is detrimental.
-
公开(公告)号：WO2010006059A8
公开(公告)日：2010-09-02
申请号：PCT/US2009049953
申请日：2009-07-08
Applicant: ABBOTT LAB , GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING
Inventor： GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING
IPC: A61K39/395
CPC classification number: C07K16/18 , A61K31/405 , A61K31/573 , A61K39/39533 , A61K2039/505 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
Abstract translation: 本发明包括前列腺素E2（PGE2）结合蛋白。 本发明涉及野生型，嵌合，CDR移植和人源化的抗体。 优选的抗体对前列腺素E2具有高亲和力并且在体外和体内中和前列腺素E2的活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗原结合部分可用于检测前列腺素E2和用于抑制前列腺素E2活性，例如，在患有前列腺素E2活性是有害的病症的人类受试者中。
-
-
-
-
-
-
-
-
-
Search Results
96
records
(took 0.024 seconds)
